

Firdapse[®] (amifampridine) – Updated dosing

- On May 30, 2024, the [FDA approved](#) updated dosing for Catalyst Pharmaceuticals' [Firdapse \(amifampridine\)](#), for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
- For adults (any weight) and pediatric patients (45 kg or more), the maximum dose was increased from 80 mg to 100 mg.
- For pediatric patients weighing less than 45 kg, the maximum dose was increased from 40 mg to 50 mg.
- For complete dosing and administration recommendations, refer to the Firdapse drug label.
- Firdapse is available as a functionally scored 10 mg tablet.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.